Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial

Sanjit S. Jolly, David P. Faxon, Keith A. A. Fox, Rizwan Afzal, William E. Boden, Petr Widimsky, P. Gabriel Steg, Vicent Valentin, Andrez Budaj, Christopher B. Granger, Campbell D. Joyner, Susan Chrolavicius, Salim Yusuf, Shamir R. Mehta

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines.

Background The OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial showed that fondaparinux reduced major bleeding by 50% compared with enoxaparin while preserving similar efficacy. Whether this benefit is consistent in the presence or absence of concurrent antiplatelet therapy with clopidogrel and GP IIb/IIIa inhibitors is unknown.

Methods Patients with ACS (n = 20,078) were randomized as a part of the OASIS 5 trial to receive either fondaparinux or enoxaparin. The use of GP IIb/IIIa inhibitors or thienopyridines was at the discretion of the treating physician. A Cox proportional hazard model was used to compare outcomes.

Results Of the 20,078 patients randomized, 3,630 patients received GP IIb/IIIa and 13,531 received thienopyridines. There was a 40% reduction in major bleeding with fondaparinux compared with enoxaparin in those treated with GP IIb/IIIa (5.2% vs. 8.3%, hazard ratio [HR]: 0.61, p < 0.001). A similar reduction was found in those treated with thienopyridines (3.4% vs. 5.4%, HR: 0.62, p < 0.001). Ischemic events were similar between the groups, resulting in a superior net clinical outcome (death, myocardial infarction, refractory ischemia, or major bleeding) favoring fondaparinux (GP IIb/IIIa subgroup 14.8% vs. 18.9%, HR: 0.77, p = 0.001 and thienopyridines subgroup 11.0% vs. 13.2%, HR: 0.82, p < 0.001).

Conclusions In patients receiving GP IIb/IIIa inhibitors or thienopyridines, fondaparinux reduces major bleeding and improves net clinical outcome compared with enoxaparin.

Original languageEnglish
Pages (from-to)468-476
Number of pages9
JournalJournal of the American College of Cardiology
Volume54
Issue number5
DOIs
Publication statusPublished - 28 Jul 2009

Keywords

  • anticoagulants
  • acute coronary syndromes
  • hemorrhage

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial'. Together they form a unique fingerprint.

Cite this